Biolinerx Teams with Jiangsu for Hepatitis C Drug in China
By Shannon Ellis
Wednesday, June 19, 2013
SHANGHAI, China – A licensing agreement may help troubled Israeli firm Biolinerx Ltd. get a toehold in China with its hepatitis C virus (HCV) treatment BL-8030.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.